RecruitingNCT04330118

Origin and Function of Eosinophilic Polynuclear During DRESS Syndrome

Origin and Function of Eosinophilic Polynuclear During Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome


Sponsor

University Hospital, Lille

Enrollment

80 participants

Start Date

Jul 15, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

Drug Hypersensitivity Syndrome or DRESS for "Drug Reaction with Eosinophilia and Systemic Symptoms" is a serious drug allergy which can be life-threatening for patients with serious organ damage. The pathophysiology of DRESS is still not fully understood. In particular, no study has focused on the characterization of eosinophils, while paradoxically eosinophilia is one of the diagnostic criteria. Likewise, there is no data about the origin of eosinophils and few data are available concerning immune polarization of T-cells or the involvement of innate lymphoid cells type 2 in the recruitment of eosinophils. Our preliminary data on increase activation markers membrane expression of cutaneous eosinophils suggest that this approach could allow the identification of endotypes in which eosinophils are involved and contribute to organ damages. The correlation between tissue infiltration of eosinophils and their degree of activation would then justify the development of targeted therapeutic strategies in DRESS syndrome (anti-IL-5 therapy?). The aim of the project is: 1) Evaluate the activation status of circulating and cutaneous eosinophils in patients with DRESS compared with drug induced maculopapular exanthema without or with eosinophilia (but do not fulfill DRESS criteria) and healthy subjects; 2) Understand the pathophysiological mechanisms at the origin of this eosinophilia.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with dress syndrome and drug hypersensitivity. The study is currently recruiting participants at 11 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(11)

CH d'Arras

Arras, France

CH de Boulogne

Boulogne-sur-Mer, France

Assistance Publique - Hôpitaux de Paris - HENRI MONDOR

Créteil, France

CH de Douai

Douai, France

CH de Dunkerque

Dunkirk, France

CH LENS

Lens, France

Hop Claude Huriez Chr Lille

Lille, France

Groupe Hospitalier de l'Institut Catholique de Lille

Lille, France

CH de Roubaix

Roubaix, France

Hôpital FOCH

Suresnes, France

CH de Valenciennes

Valenciennes, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04330118


Related Trials